drugset / Trial / NCT05941793
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of SNS812 in Participants with Mild to Moderate COVID-19
Timeline
- Start
- 2023-09-11
- Primary completion
- 2024-08-12
- Completion
- 2024-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBS-COV | Unknown | — | Inhaled |
Indications
No indication recorded.